Tetra Bio Pharma Inc TBPMQ

Healthcare Cannabis

Tetra Bio-Pharma Inc. is a Canada-based cannabinoid-derived drug discovery and development company. The Company has developed a pipeline of cannabinoid-based drug products for a range of medical conditions, including pain, inflammation, and oncology. The Company has a pipeline of formulations and drug delivery systems with a portfolio of assets from the early research and development phase to advanced stage clinical programs. Its products include QIXLEEF, CAUMZ, PPP004, REDUVO, and REBORN 1. QIXLEEF is a botanical therapy with a fixed dosage of tetrahydrocannabinol (THC) and cannabidiol (CBD). CAUMZ is its inhaled cannabinoid-derived drug candidate. PPP004 is a topical preparation containing either a standardized amount of CBD or a defined ratio of THC and CBD. REDUVO is a soft gel capsule used to treat chemotherapy-induced nausea and vomiting (CINV) and weight loss and severe nausea in people living with human immunodeficiency virus (HIV) infection. REBORN 1 is in phase II trial.

GREY:TBPMQ - Post by User

Tetra Bio Pharma Inc > Some kind of update is required

<< Previous

Bullboard Posts

Next >>

Comment by Davesnothereon Feb 09, 2022 9:40am

110 Views

Post# 34411878

RE:RE:Some kind of update is required

Golddetector wrote: Tetra has to do a better job in IR. The latest nr was back in Nov. maybe they are expecting Reduvo anytime now. It was initially expected in Nov last year. Already 3 months late. The reborn is still to come in March.

Agree with you Gold, for some reason Tetra does not put much effort into IR. Never have.

Sometimes they make a big deal out of small things, other times they do not promote bigger steps!

Shareholders need a lot of Patience :(

<< Previous

Bullboard Posts

Next >>

How one company is disrupting PoC testing